AccuMedical

AccuMedical Beijing Ltd.(referred to as: AccuMedical) was established in 2017, with its headquarters and production center located in Beijing, and its R&D center in California, USA, possessing complete R&D, production, and sales capabilities. AccuMedical is committed to developing a series of innovative neurointerventional devices for the diagnosis and treatment of hemorrhagic stroke and ischemic stroke, as well as related access devices. Currently, the company has three products approved by NMPA — the Cosine Distal Access Catheter, Sine Microcatheter, and Lattice Flow Diverter. The Lattice Flow Diverter is one of the leading products of our company. In May 2020, this product was approved to enter the National Innovative Medical Device Rapid Approval Channel; on August 12, 2022, the results of the pre-market clinical trial - LIFE (Lattice Intracranial Flow Diverter Evaluation of Clinical Use) were released at the 19th China Cerebrovascular Disease Forum (CFCVD2022); on October 24, 2022, it was approved by NMPA for marketing!